慢病毒载体在β地中海贫血基因治疗中的研究进展

doi:10.16352/j.issn.1001-6325.2023.12.1876

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (12): 1876-1880.doi: 10.16352/j.issn.1001-6325.2023.12.1876

慢病毒载体在β地中海贫血基因治疗中的研究进展

刘译泽¹, 镡颖^1,2, 朱宝生^1,2*

1.昆明理工大学医学院,云南昆明 650500;
2.云南省第一人民医院昆明理工大学附属医院医学遗传科,云南昆明 650032

收稿日期:2022-11-01 修回日期:2023-06-12 出版日期:2023-12-05 发布日期:2023-11-29
通讯作者: ^* bszhu@aliyun.com
基金资助:
国家自然科学基金地区基金( 82060039);云南省科技计划(202101AS070005)

Lentivirus vector in gene therapy of β-thalassemia

LIU Yize¹, CHAN Ying^1,2, ZHU Baosheng^1,2*

1. School of Medicine, Kunming University of Science and Technology,Kunming 650500;
2. Department of Medical Genetics, the First People's Hospital of Yunnan Province,the Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, China

Received:2022-11-01 Revised:2023-06-12 Online:2023-12-05 Published:2023-11-29
Contact: ^* bszhu@aliyun.com

摘要/Abstract

摘要： β地中海贫血(β地贫)是一种由β珠蛋白基因突变导致β珠蛋白合成障碍或结构改变而引起的常见遗传性血液病。当前针对β地贫的慢病毒载体(LVV)介导的基因治疗,主要分为利用LVV将具有完整功能的β-血红蛋白基因添加在染色体上的基因整合策略,以及利用LVV将特异性核酸酶递送到造血干细胞中,对β-珠蛋白(HBB)基因进行原位修复的基因组编辑策略。提高病毒滴度与转导效率、降低脱靶率及推进临床试验是这两种策略的主要研究方向。

关键词: 慢病毒载体, 基因治疗, β地中海贫血

Abstract: β-thalassemia is a common monogenic inherited blood disorder caused by mutations of β-globin gene which results to synthesis obstacles or abnormal structure of β-globin. Gene therapy mediated by lentiviral vector(LVV) is divided into gene-integration strategies using LVV to add fully functional β-hemoglobin(HBB) genes to chromosomes and gene-editing strategies using LVV to deliver specific ribozymes to hematopoietic stem cells for in situ repair of HBB genes. Improving viral titration and transduction efficiency, reducing target loss and advancing clinical trials are the main targets of these two strategies.

Key words: lentivirus vector, gene therapy, β-thalassemia

中图分类号:

R459.9

刘译泽, 镡颖, 朱宝生. 慢病毒载体在β地中海贫血基因治疗中的研究进展[J]. 基础医学与临床, 2023, 43(12): 1876-1880.

LIU Yize, CHAN Ying, ZHU Baosheng. Lentivirus vector in gene therapy of β-thalassemia[J]. Basic & Clinical Medicine, 2023, 43(12): 1876-1880.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.12.1876

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I12/1876

参考文献 25

[1]	Yu FH, Huang KJ, Wang CT. HIV-1 mutant assembly, processing and infectivity expresses pol independent of gag[J]. Viruses, 2020, 12:54-59.
[2]	Lee S, Cobrinik D. Improved third-generation lentiviral packaging with pLKO.1C vectors[J]. Biotechniques 2020, 68:349-352.
[3]	Yudovich D, Backstrom A, Schmiderer L, et al. Comb-ined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells[J]. Sci. Rep, 2020, 10:22393.doi: 10.1038/s41598-020-79724-x.
[4]	Nualkaew T, Sii-Felice K, Giorgi M, et al. Coordinated β-globin expression and α2-globin reduction in a multiplex lentiviral[J]. Mol Ther, 29:2841-2853.
[5]	于榛, 仝帅, 白玥, 等. 优化第三代慢病毒载体稳定表达β-珠蛋白治疗β-地中海贫血的研究[J]. 中国实验血液学杂志, 2022, 30:844-850.
[6]	Lamsfus-Calle A, Daniel-Moreno A, Urena-Bailen G, et al. Hematopoietic stem cell gene therapy: the optimal use of lentivirus and gene editing approaches[J]. Blood Rev, 2020, 40:100641.doi: 10.1016/j.blre.2019.100641. Epub 2019 Nov 15.
[7]	Morgan RA, Unti MJ, Aleshe B, et al. Improved titer and gene transfer by lentiviral vectors using novel, small beta-globin locus control region elements[J]. Mol Ther, 2020, 28:328-340.
[8]	Ouyang WJ, Dong GY, Zhao WH, et al. Restoration of beta-globin expression with optimally designed lentiviral vector for beta-thalassemia treatment in chinese patients[J]. Hum Gene Ther, 2021, 32:481-494.
[9]	Schott JW, Leon-Rico D, Ferreira CB, et al. Enhancing lentiviral and alpharetroviral transduction of human hematopoietic stem cells for clinical application[J]. Mol Ther Methods Clin Dev, 2019, 14:134-147.
[10]	Ozog S, Timberlake ND, Hermann K, et al. Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes[J]. Blood, 2019, 134:1298-1311.
[11]	Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene autotemcel gene therapy for non-beta(0)/beta(0) genotype beta-thalassemia[J]. N Engl J Med, 386:415-427.
[12]	Magrin E, Semeraro M, Hebert N, et al. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial[J]. Nat Med, 2022, 28:81-88.
[13]	Hongeng S, Anurathapan U, Songdej D, et al. Wild-type HIV infection after treatment with lentiviral gene therapy for beta-thalassemia[J]. Blood Adv, 2021, 5:2701-2706.
[14]	Tucci F, Galimberti S, Naldini L, et al. A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders[J]. Nat Commun, 2022, 13:1315.doi: 10.1038/s41467-022-28762-2.
[15]	Cosenza LC, Zuccato C, Zurlo M, et al. Co-treatment of erythroid cells from beta-thalassemia patients with CRISPR-Cas9-based beta(0)39-globin gene editing and induction of fetal hemoglobin[J]. Genes, 2022, 13:1727.doi: 10.3390/genes13101727.
[16]	Ling S, Yang S, Hu X, et al. Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA [J]. Nat Biomed Eng, 2021, 5:144-156.
[17]	Ortinski PI, O′donovan B, Dong X, et al. Integrase-deficient lentiviral vector as an all-in-one platform for highly efficient CRISPR/Cas9-mediated gene editing[J]. Mol Ther Methods Clin Dev, 2017, 5:153-164.
[18]	Li QY, Gao YM, Wang HF. CRISPR-based tools for fighting rare diseases[J]. Life-Basel, 2022, 12:1968.doi: 10.3390/life12121968.
[19]	Kwon J, Kim M, Hwang W, et al. Extru-seq: a method for predicting genome-wide Cas9 off-target sites with[J]. Genome Biol, 2023, 24:4.doi: 10.1186/s13059-022-02842-4.
[20]	Apolonia L. The old and the new: prospects for non-Integrating lentiviral vector technology[J]. Viruses-Basel, 2020, 12:1016.doi: 10.3390/v12101103.
[21]	Gee P, Lung MSY, Okuzaki Y, et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping[J]. Nat Commun, 2020, 11:1334.doi: 10.1038/s41467-020-14957-y.
[22]	Mangeot PE, Risson V, Fusil F, et al. Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins[J]. Nat Commun, 2019, 10:45.doi: 10.1038/s41467-018-07845-z.
[23]	Indikova I, Indik S. Highly efficient ‘hit-and-run’ genome editing with unconcentrated lentivectors carrying Vpr.Prot.Cas9 protein produced from RRE-containing transcripts[J]. Nucleic Acids Res, 2020, 48:8178-8187.
[24]	Uchida N, Ferrara F, Drysdale CM, et al. Sustained fetal hemoglobin induction in vivo is achieved by BCL11A interference and coexpressed truncated erythropoietin receptor[J]. Sci Transl Med, 2021, 13:eabb0411.doi: 10.1126/scitranslmed.abb0411.
[25]	Liu BY, Brendel C, Vinjamur DS, et al. Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat ll-hemoglobinopathies br[J]. Mol Ther, 2022, 30:2693-2708.

慢病毒载体在β地中海贫血基因治疗中的研究进展

Lentivirus vector in gene therapy of β-thalassemia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘婧雯, 宋昊昕, 朱蕾. 稳定表达FIP1L1-PDGFRA及其突变体细胞株的构建和耐药性评价[J]. 基础医学与临床, 2024, 44(1): 63-68.
[2]	李晓光, 杨璐, 刘旭东, 贾鑫淼, 杨欣壮, 崔丽英. 基因治疗肌萎缩侧索硬化机制的研究进展[J]. 基础医学与临床, 2023, 43(4): 674-679.
[3]	刘健. 基因治疗中的核酸药物及非病毒递送载体的研究进展[J]. 基础医学与临床, 2022, 42(1): 41-50.
[4]	杨小娟, 李振昊, 苟元凤, 火夏琴, 裴亚萍, 李娜, 刘会玲. 腺相关病毒介导的基因治疗在肿瘤中的研究进展[J]. 基础医学与临床, 2021, 41(4): 573-577.
[5]	李雅惠, 李凯, 罗艳云, 李梦真, 邙新雨, 宋伟, 杨涛. 小鼠生精细胞特异表达载体AAV-Dazl-RFP-Flag的构建及表达验证[J]. 基础医学与临床, 2020, 40(6): 753-758.
[6]	孙兆庆闫波. CRISPR/ Cas9基因编辑技术在心血管领域中的研究进展[J]. 基础医学与临床, 2019, 39(6): 890-894.
[7]	任静李毅杨慧鲁玲玲. 慢病毒载体介导下DJ-1过表达细胞模型的建立[J]. 基础医学与临床, 2018, 38(1): 1-6.
[8]	张军峰史利利张力李红波张建水祁存芳刘勇徐曦. HRE介导的NT-3表达上调减轻大鼠局灶性脑缺血再灌注损伤[J]. 基础医学与临床, 2015, 35(9): 1199-1204.
[9]	邓益斌农乐根梁祚仁覃羽华. LNAzyme特异性阻断丙肝病毒5′-NCR/C基因表达[J]. 基础医学与临床, 2015, 35(7): 938-942.
[10]	邢译文白静范维宁刘鑫周林林徐广贤. OPN siRNA慢病毒载体的构建及其对大肠癌细胞增殖抑制作用[J]. 基础医学与临床, 2014, 34(3): 350-354.
[11]	罗艳红邓益斌邹佳峻. 反基因锁核酸体外阻断肝癌细胞株乙肝病毒S基因表达[J]. 基础医学与临床, 2014, 34(2): 206-210.
[12]	章杰江华刘安堂朱鴷张文俊芦立轩. 敲减水通道蛋白1对小鼠雪旺细胞形态及水转运的影响[J]. 基础医学与临床, 2014, 34(1): 29-35.
[13]	邓益斌温旺荣. 反基因锁核酸体外抑制乙肝病毒前S1基因表达[J]. 基础医学与临床, 2013, 33(6): 722-725.
[14]	田锋钱海利林晨王任直. 人生长激素启动子调控TNF-α表达载体的构建及体外靶向基因治疗垂体生长激素腺瘤[J]. 基础医学与临床, 2013, 33(5): 572-577.
[15]	吴小妹曾敏谭利明黄志凌朱灿刘飞. 腺苷增强治疗（AATs）在癫痫治疗的研究进展[J]. 基础医学与临床, 2013, 33(10): 1352-1355.